Druggability & Clinical Context
Druggability
Low
Score: 0.33
Target Class
Structural Protein
Druggability Analysis
Structural Tractability0.85
Key Metrics
PDB Structures:
49
Known Drugs:
1
Approved:
1
In Clinical Trials:
0
Drug Pipeline (1 compounds)
1 Approved
Therapeutic Areas:Movement disorders Spasticity Essential tremor Cervical dystonia Neurodegenerative diseases Psychiatric disorders with synaptic dysfunction Overactive bladder Chronic pain
Druggability Rationale: SNAP25 presents medium druggability with validated proof-of-concept from approved botulinum toxin therapeutics, supported by 49 PDB structures at 1.5Å resolution and AlphaFold modeling. However, as a structural protein mediating protein-protein interactions within the SNARE complex, direct small molecule inhibition faces challenges in achieving specificity and sufficient binding affinity to compete with native protein-protein interactions.
Mechanism: Protein cleavage by botulinum toxin or small molecule modulators of SNARE complex formation
Drug Pipeline (1 compounds)
1 Approved
Known Drugs:Botulinum toxin A (approved) — Movement disorders, spasticity
Structural Data:PDB (49) ✓AlphaFold ✓Cryo-EM —
Binding Pocket Analysis:Structural data reveals potential allosteric binding sites on SNAP25 distinct from the SNARE-complex interaction interface, particularly at the regulatory N-terminal region. The 49 available crystal structures identify transient pockets suitable for modulator binding that could allosterically modulate SNARE assembly without directly competing with cognate SNARE partners.
Selectivity & Safety Considerations
SNAP25 selectivity is complicated by its structural homologs SNAP23 and SNAP29, which share significant sequence identity and could lead to off-target engagement. Achieving isoform selectivity through small molecules targeting the SNARE-binding interface will require structure-guided design to exploit subtle conformational differences.
Clinical Trials (2)
Relevant trials from ClinicalTrials.gov
NA
NCT04383912
n=16
Direct Brow Lift, Scarring
Interventions: Botox Injectable Product, No intervention (placebo)
Sponsor: Nova Scotia Health Authority | Started: 2020-11-18
NA
NCT00999869
n=20
Alopecia Areata
Interventions: Botulinum toxin type A, Triamcinolone acetonide
Sponsor: Siriraj Hospital | Started: 2009-11